We are live on
!
Find out more
CM
CM Management Portfolio holdings
AUM
$157M
Turnover
30.95%
1-Year Est. Return
60.08%
This Fund
S&P 500
This Quarter
Est. Return
-6.85%
1 Year Est. Return
+60.08%
3 Year Est. Return
+110.48%
5 Year Est. Return
+186.03%
10 Year Est. Return
–
AUM
$109M
AUM Growth
-$10.1M
(-8.5%)
Cap. Flow
+$2.31M
Cap. Flow
% of AUM
2.12%
Top 10 Holdings %
Top 10 Hldgs %
38.45%
Holding
73
New
4
Increased
25
Reduced
5
Closed
10
Avg Time Held
1.8
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$1.88M |
| 2 |
ARKO Corp
ARKO
|
+$1.61M |
| 3 |
Baidu
BIDU
|
+$1.51M |
| 4 |
First Financial Corp
THFF
|
+$955K |
| 5 |
Talos Energy
TALO
|
+$935K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
American Superconductor
AMSC
|
+$3.38M |
| 2 |
Rigel Pharmaceuticals
RIGL
|
+$2.96M |
| 3 |
Incyte
INCY
|
+$1.71M |
| 4 |
First Horizon
FHN
|
+$1.54M |
| 5 |
Tejon Ranch
TRC
|
+$693K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.69% |
| 2 | Technology | 11.09% |
| 3 | Materials | 10.64% |
| 4 | Consumer Staples | 8.17% |
| 5 | Consumer Discretionary | 7.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
VRNA
51
DELISTED
Verona Pharma
VRNA
| $506K | 0.46% |
35,000
| – | – |
2024 Q1
1 quarter
|
|
52
Femasys
FEMY
$14.4M
| $485K | 0.44% |
21,250
+1,250
| +6% | +$31.9K |
2021 Q2
12 quarters
|
|
53
Battalion Oil
BATL
$59.6M
| $468K | 0.43% |
140,000
+10,000
| +8% | +$53.4K |
2020 Q4
14 quarters
|
|
54
DELISTED
Assertio
ASRT
| $434K | 0.4% |
23,333
+333
| +1% | +$4.95K |
2023 Q2
4 quarters
|
|
55
Eledon Pharmaceuticals
ELDN
$183M
| $422K | 0.39% |
160,000
| – | – |
2021 Q1
13 quarters
|
|
56
Edesa Biotech
EDSA
$24.7M
| $385K | 0.35% |
90,000
+28,000
| +45% | +$125K |
2022 Q3
7 quarters
|
|
57
Lantern Pharma
LTRN
$10.4M
| $374K | 0.34% |
80,000
+15,000
| +23% | +$90.2K |
2022 Q1
9 quarters
|
|
58
Cognition Therapeutics
CGTX
$68.8M
| $332K | 0.3% |
200,000
+25,000
| +14% | +$49.8K |
2024 Q1
1 quarter
|
|
59
Compass Therapeutics
CMPX
$157M
| $310K | 0.28% |
310,000
| – | – |
2023 Q4
2 quarters
|
|
60
DELISTED
Cadence Bank
CADE
| $283K | 0.26% |
10,000
| – | – |
2023 Q2
4 quarters
|
|
61
Elicio Therapeutics
ELTX
$48.2M
| $206K | 0.19% |
50,000
-25,000
| -33% | -$211K |
2021 Q1
13 quarters
|
|
62
DELISTED
Kronos Bio
KRON
| $167K | 0.15% |
135,000
-115,000
| -46% | -$117K |
2022 Q4
6 quarters
|
|
63
Gain Therapeutics
GANX
$57.6M
| $115K | 0.11% |
90,000
| – | – |
2021 Q2
12 quarters
|
|
|
64
American Superconductor
AMSC
$1.27B
| – | – |
-250,000
| Closed | -$3.38M | – |
|
65
BioCardia
BCDA
$14.1M
| – | – |
-46,667
| Closed | -$285K | – |
|
|
66
First Horizon
FHN
$10.9B
| – | – |
-100,000
| Closed | -$1.54M | – |
|
|
67
Incyte
INCY
$23B
| – | – |
-30,000
| Closed | -$1.71M | – |
|
|
68
Rigel Pharmaceuticals
RIGL
$881M
| – | – |
-200,000
| Closed | -$2.96M | – |
|
69
Cartesian Therapeutics
RNAC
$198M
| – | – |
-10,183
| Closed | -$199K | – |
|
70
Smith Micro Software
SMSI
$12.8M
| – | – |
-15,000
| Closed | -$207K | – |
|
|
71
Tejon Ranch
TRC
$450M
| – | – |
-45,000
| Closed | -$693K | – |
|
72
Bristow Group
VTOL
$1.13B
| – | – |
-15,377
| Closed | -$418K | – |
|
73
Palvella Therapeutics
PVLA
$1.8B
| – | – |
-7,188
| Closed | -$105K | – |
|
Similar funds
SFSG
PTFIS
AWMG
LDNAM
DFS
APW
GA
TC
CM Management's Q2 2024 Portfolio in Review
As of Q2 2024, CM Management held 73 positions worth $109M, down 8.5% from $119M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
CM Management's Q2 2024 filing shows 4 new, 25 increased, 5 reduced and 10 closed positions. Its largest new stake was CVS Health: 30,000 shares worth $1.77M. The largest sale was American Superconductor, an estimated $3.38M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 43% a quarter earlier, followed by Technology and Materials.
- CM Management's largest Q2 2024 buy was CVS Health: 30,000 shares worth $1.77M.
- CM Management added most to ARKO Corp in Q2 2024, an estimated $1.61M increase.
- CM Management's biggest Q2 2024 reduction was Pan American Silver, cutting an estimated $493K.
- CM Management fully exited American Superconductor in Q2 2024, selling an estimated $3.38M.
- CM Management's ten largest holdings make up 38% of its $109M portfolio in Q2 2024.
- CM Management opened 4 new positions and closed 10 in Q2 2024.
- CM Management's portfolio value fell 8.5% quarter-over-quarter to $109M.
Based on CM Management's 13F filing for Q2 2024, filed 1 Aug 2024.